"It's not the tragedies that define our lives, but the choices we make to face them"

Arrow up
Arrow down
Set 02, 2022

Antibiotic resistance: the WHO report

According to the WHO, the development of new antibacterial treatments is inadequate to address the mounting threat of antibiotic resistance.

The 2021 report describes the antibacterial clinical and preclinical pipeline as stagnant and far from meeting global needs.

In this article, we take a look at some interesting findings from the report and the benefits of Kitelock in terms of antibiotic resistance.

Antibiotic resistance: some data from the 2021 WHO report

According to the WHO analysis, since 2017 only 12 antibiotics have been approved, 10 of which belong to existing classes with established mechanisms of antimicrobial resistance (AMR).

Not only that. In 2021 there were only 27 new antibiotics in clinical development against priority pathogens, down from 31 products in 2017.

Of these 27 antibiotics in the clinical pipeline, only 6 fulfil at least one of WHO’s criteria for innovation. And it is this lack of innovation that is rapidly undermining the effectiveness of the limited number of new antibiotics reaching the market.

On average resistance to most new agents is reported 2-3 years after market entry. Major barriers to new product development include:

  • long approval pathway;
  • high costs;
  • low success rates.

To date, in fact, it takes about 10-15 years to progress an antibiotic candidate from the preclinical to the clinical stages. For antibiotics in existing classes, on average, only one of every 15 drugs in preclinical development will reach patients. For new classes of antibiotics, only one in 30 candidates.

To learn more, here you can find the WHO report "2021 Antibacterial agents in clinical and preclinical development: an overview and analysis".

KitelockTM: lock solution for catheters, without antibiotics

KitelockTM is a lock solution for catheters that helps reduce risks and complications for patients requiring a venous access device.

Disposable, transparent and colorless, it is a 4% tetrasodium edetate solution and is characterized by performing a triple action:

  • anticoagulant;
  • antibacterial;
  • anti-biofilm.

KitelockTM contains no preservatives, no alcohol and no latex. In addition, Tetrasodium EDTA is a non-antibiotic agent (therefore it does not contribute to antibiotic resistance) and is extremely safe: unlike common doses of edetate used in chelating therapies, the concentration present in KitelockTM does not expose the patient to physiological, pharmacological, therapeutic, or adverse effects.

The use of this device allows to maintain patency inside the catheter, reducing the rate of bacterial colonization in patients with dialysis catheters up to 87%. KitelockTM can be successfully used in catheters of different materials: both those made of Silastic and polyurethane.

Would you like more information about the advantages of this catheter lock solution? Contact us without obligation to get all the details from one of our professionals.


In this page you can find all the latest news about Delta Med medical devices, product catalog updates and official press releases of the company. Would you like to receive all the latest information about us? Subscribe to our newsletter by filling out the appropriate form.

Stay update!